Faculty of Medical and Health Sciences and Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand.
Whangārei Hospital, Northland District Health Board, Whangārei, New Zealand.
ANZ J Surg. 2022 Jul;92(7-8):1748-1753. doi: 10.1111/ans.17851. Epub 2022 Jun 28.
Small intestinal Neuroendocrine Neoplasms (SI-NENs) are the most common primary malignancy of the small bowel. The aim of this study is to define the survival of patients with an SI-NEN in Auckland, Aotearoa New Zealand (AoNZ).
A retrospective study of all patients diagnosed with a jejunal or ileal SI-NEN in the Auckland region between 2000 and 2012 was performed. The New Zealand NETwork! Registry was searched to identify the study cohort. Retrospective data collection was performed to collect stage, survival and follow up data.
One hundred and seven patients were included in the study. The mean age of patients was 62.8 years (SD 11.9). The 5 and 10-year disease-specific survival for all patients was 66.1% (95% CI 56.5-75.7%) and 61.8% (95% CI 51.8-71.8%), respectively. Ten-year disease-specific survival was 100% for stage I and II, 74% (95%CI 61.7-84.4%) for stage III and 33.9% (95%CI 16.9-35.6%) for stage IV SI-NEN. Eleven of 40 (27.5%) patients with stage III disease had recurrence and 3 of 7 (42.8%) patients with stage IV disease had recurrence. In patients with stage IV disease, neither primary resection (HR 2.25, 95% CI 0.92-5.5) nor distant resection (HR 1.72, 95% CI 0.63-4.7) were significantly associated with a disease-specific or overall survival benefit.
This study demonstrates that stage at SI-NEN diagnosis is associated with survival, but resection of the primary or distant metastases in patients with stage IV disease is not. There was no recurrence in patients with stage I or II disease after complete resection.
小肠类癌（SI-NENs）是小肠最常见的原发性恶性肿瘤。本研究旨在定义新西兰奥克兰（AoNZ）患者的 SI-NEN 生存情况。
对 2000 年至 2012 年间在奥克兰地区诊断为空肠或回肠 SI-NEN 的所有患者进行了回顾性研究。新西兰 NETwork! Registry 被用来确定研究队列。回顾性收集了分期、生存和随访数据。
共有 107 名患者纳入研究。患者的平均年龄为 62.8 岁（标准差 11.9）。所有患者的 5 年和 10 年疾病特异性生存率分别为 66.1%（95%CI 56.5-75.7%）和 61.8%（95%CI 51.8-71.8%）。I 期和 II 期的 10 年疾病特异性生存率为 100%，III 期为 74%（95%CI 61.7-84.4%），IV 期为 33.9%（95%CI 16.9-35.6%）。III 期疾病的 40 例患者中有 11 例（27.5%）复发，IV 期疾病的 7 例患者中有 3 例（42.8%）复发。在 IV 期疾病患者中，原发灶切除（HR 2.25，95%CI 0.92-5.5）或远处转移灶切除（HR 1.72，95%CI 0.63-4.7）均与疾病特异性或总体生存获益无显著相关性。
本研究表明，SI-NEN 诊断时的分期与生存相关，但在 IV 期疾病患者中切除原发灶或远处转移灶并不能带来生存获益。完全切除后，I 期或 II 期疾病患者无复发。
